AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Sichuan Kelun-Biotech Inks Oncology Partnership with Crescent Biopharma
ByAinvest
Thursday, Dec 4, 2025 11:26 pm ET1min read
Sichuan Kelun-Biotech Biopharmaceutical has signed an oncology partnership with Crescent Biopharma, leading to a 3% rise in shares. The China-based company focuses on research and development, production, and sales of drugs, primarily in oncology, immunology, and other therapeutic fields. Its products include antibody-drug conjugates SKB264 and A166, used for treating breast cancer, non-small cell lung cancer, and gastrointestinal cancer.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet